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a b s t r a c t
High prevalence of psychological comorbidities such as depression and anxiety in patients with
inﬂammatory bowel disease (IBD) supports the premise that adding an anti-depressant drug with
known anti-inﬂammatory effect to the medical treatment have beneﬁcial effect in the course of the
underlying disease. Colitis was induced by intracolonic instillation of 2 ml of 4% v/v acetic acid solution
in rats. Anti-colitic effect of ﬂuvoxamine was evaluated in two categories: A: normal rats, B: reserpinized
(6 mg/kg, i.p.) depressed rats. In group A, ﬂuvoxamine (2.5, 5, 10 mg/kg, i.p.) was administered 2 h after
induction of colitis and in group B: reserpine (6 mg/kg, i.p.) was administered 1 h prior to colitis
induction and then ﬂuvoxamine (2.5, 5, 10 mg/kg, i.p.) was administered 2 h after colitis induction.
Dexamethasone (1 mg/kg) was used as reference drug. All the treatments continued daily for ﬁve days.
The effect was assessed on the basis of macroscopic score, biochemical (myeloperoxidase) changes and
histopathological studies. Results showed that ﬂuvoxamine (2.5 and 5 mg/kg) and dexamethasone
treatment markedly reduced disease severity in both reserpinized and non-reserpinized rats as indicated
by reduction in macroscopic and microscopic colonic damages while reserpine adversely exacerbated
the colitis damage. Myeloperoxidase activity which was increased following colitis induction was also
decreased. The ﬁndings of this study elucidate the anti-colitic and anti-inﬂammatory properties of
ﬂuvoxamine and so introduced it as a good candidate to treat depressive symptoms in people comorbid
to IBD.
& 2014 Elsevier B.V. All rights reserved.
1. Introduction
Inﬂammatory bowel disease (IBD), which include Crohn's disease
(CD) and ulcerative colitis (UC) is characterized by episodes of
exacerbations and remissions (Bernstein et al., 2009). Patients fre-
quently suffer from abdominal pain, diarrhea along with blood and/or
mucus, fever, weight loss, fatigue, inﬂammation, ulceration and
edema (Thoreson and Cullen, 2007). The chronic course of the disease
can cause awide range of psychological and interpersonal concerns to
patients. Indeed, symptoms, such as fecal incontinence or soiling and
lack of bowel control, can lead to a loss of self-unworthiness or cause
stigmatization in patients (Sajadinejad et al., 2012). There have been
many reports over the years that prevalence of psychiatric illness in
particular anxiety and depressive disorders are signiﬁcantly more
common in patients with IBD compared to the general population
(Kurina et al., 2001) and the symptoms of these conditions are more
severe during periods of active disease (Graff et al., 2009). Studies
show a 30% rate of depression during remission, with 80% and 55% of
patients reporting anxiety and depression, respectively, during relapse
(Mikocka-Walus et al., 2012a). There is increasing evidence that
depressive mood exerts negative effects on the course of several
chronic diseases (Turner and Kelly, 2000). As IBD is a chronic and
relapsing gastrointestinal disorder, it is not separate from this rule. A
recent pilot study in patients with ulcerative colitis and a conserved
colon demonstrated that depression was a risk factor of relapse
(Häuser et al., 2011). So, questions of quality of life and of coping
strategies with the disease are particularly important. Gastroenterol-
ogists reported that treating psychological co-morbidities with anti-
depressants was successful in reducing pain, gut irritability, urgency
of defecation and to control disease activity and lengthen remission
(Mikocka-Walus et al., 2006, 2012b). Furthermore anti-inﬂammatory
and analgesic effects of some anti-depressant drugs such as amitripty-
line (Sadeghi et al., 2011), maprotiline (Hajhashemi et al., 2010a),
venlafaxine (Aricioğlu et al., 2005) and ﬂuoxetine (Abdel-Salam et al.,
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2004) have been evaluated. Systematic reviews by Mikocka-Walus
et al. (2007, 2008, 2012a) indicate that antidepressants appeared not
only to help certain individual patients with IBD to cope with their
emotional problems, but also improved their quality of life. The
published observations also hold out the intriguing possibility that
anti-depressant therapy may have speciﬁcally inﬂuenced the course
of their inﬂammatory disease. Due to lower rate of side effect in
comparison to other anti-depressant drugs, SSRIs are the most wide
group which is used for treating depressive symptoms (Filipovic and
Filipovic, 2014). Following administration of SSRIs (citalopram, sertra-
line) in patients with IBD, they felt that psychological problems
responded well to this treatment however these drugs have no
beneﬁcial effect on somatic aspects of the disease (Mikocka-Walus
et al., 2007). Furthermore, ﬂuoxetine was found to protect against
colitis in a randomized controlled trial (Itatsu et al., 2011). So the
present study aims at evaluating the effect of ﬂuvoxamine as a potent
SSRI drug with known anti-inﬂammatory properties, on experimental
colitis in normal and reserpine induced depressed rats.
2. Materials and methods
2.1. Animals
Male Wistar rats (200–250 g) obtained from the laboratory
animal house of the School of Pharmacy, Isfahan University of
Medical Sciences, Iran, were used in this experiment. Animals
were kept at controlled environmental conditions where the
temperature of the experimental room was maintained at
20–23 1C, relative humidity at 50–60% with a 12:12 h light/dark
cycle. All animals were given access to a standard pellet diet and
water. Animals were housed individually in standard cages and
were acclimatized for 7 days before initiation of the treatment. The
animal study was approved by the guideline of the ethical
committee of Isfahan University of Medical Sciences.
2.2. Chemicals
Fluvoxamine maleate was a gift from Abidi Pharmaceutical
Company (Tehran, Iran). Dexamethasone was also a gift from Raha
Pharmaceutical Company (Isfahan, Iran). Reserpine, hexadecyl
trimethyl-ammonium bromide (HTAB) and O-dianisidine dihy-
drochloride were purchased from Sigma Chemical Co. (St. Louis,
Mo, USA). Formalin solution 35% w/w, glacial acetic acid and diethyl
ether oxide were purchased form Merck (Darmstadt, Germany). All
other solvents and chemicals were of analytical grade.
2.3. Behavioral tests
2.3.1. Determination of anti-depressant dose of ﬂuvoxamine
in reserpinized depressed rats
This part of experiment was designed to determine the optimum
dose of ﬂuvoxamine which has anti-depressant effect in reserpinized
depressed animals to be used in colitis part of the experiment. So rats
were randomly assigned to six groups of rats comprising six rats per
group as follows: Sham group received normal saline (2 ml/kg, i.p.)
daily for four days. Control group received a single dose of reserpine
(6 mg/kg, i.p.) and was treated with normal saline 3 h after reserpine
injection and then daily for four days. Test groups received a single
dose of reserpine (6 mg/kg, i.p.) and then were treated with ﬂuvox-
amine (1.25, 2.5, 5, and 10 mg/kg, i.p.) 3 h after reserpine injection
and daily for four days. Then animals were subjected to forced
swimming test. So at the third day, the rats were individually placed
in a cylinder containing water 15 cm in height at 25 1C for 15 min
(pre-test). On the following day (fourth day) the rats were again
immersed inwater and total duration of immobility wasmeasured for
5 min. The immobility time was regarded as the time that the rat
spent ﬂoating in the water without struggling and making only those
movements necessary to keep its head above water (Porsolt et al.,
1978).
2.4. Body weight measurement
Every morning at the start of the experiment and daily there-
after, animals were individually weighed by a digital scale (ACCU-
LAB V-3000) and the body weight was recorded subsequently in
order to measure body weight change and also to calculate all drug
doses as mg/kg base (Niu et al., 2013).
2.5. Induction of experimental colitis
Acute colitis was induced by acetic acid using a technique
introduced by MacPherson and Pfeiffer (1978). Brieﬂy, rats were
fasted for 24 h before induction of colitis in stainless steel cages
with free access to water. The rats were lightly anesthetized with
ether and a ﬂexible plastic catheter with an outside diameter of
2 mmwas inserted 8 cm into the colon via the anus. Two milliliter
of acetic acid (4% v/v in 0.9% saline) was slowly infused into the
colon. Animals were then maintained in a head down position for
30 s to limit expulsion of the solution and returned.
2.6. Animal grouping
The rats were randomly divided into the following groups of six
rats in each: Sham group: received normal saline (2 ml/kg, i.p.)
without induction of colitis; control group: received normal saline
(2 ml/kg, i.p.) following induction of colitis; dexamethasone
group: dexamethasone (1 mg/kg, i.p.) was given 2 h following
induction of colitis. Test groups include non-reserpine treated
groups which received ﬂuvoxamine (2.5, 5, 10 mg/kg, i.p.) 2 h
following induction of colitis and reserpine treated groups which
received reserpine (6 mg/kg, i.p.) 1 h prior to induction of colitis
and then treated with ﬂuvoxamine (2.5, 5, 10 mg/kg, i.p.) 2 h
following induction of colitis. Administration of medications was
performed for the following four days. All the drug doses were
prepared freshly each morning.
2.7. Assessment of colon macroscopic damage
The rats were killed 24 h after the last treatment (Day 5) by an
overdose of ether inhalation. The colons were dissected, slightly
rinsed with normal saline and the length and weight were
measured (Minaiyan et al., 2011). Then segments of colon were
used for the assessment of macroscopic and histopathology
damage and measurement of tissue myeloperoxidase activity.
Macroscopic damage scores were assigned by an independent
observer according to the following criteria: 0¼no macroscopic
changes, 1¼mucosal erythema only, 2¼mild mucosal edema,
slight bleeding, or slight erosion, 3¼moderate edema, bleeding
ulcers, or erosions, and 4¼severe ulceration, erosions, edema, and
tissue necrosis (Deshmukh et al., 2010). Then, tissue was ﬁxed on a
white plastic sheet and a photo was taken using an appropriately
adjusted Nikon camera (Coolpix p100) to calculate the ulcer area.
Pieces were cut into two pieces, one piece for histopathology
assessment (maintained in 5 ml formalin 10% as ﬁxator) and one
piece for measuring myeloperoxidase (MPO) enzyme activity. The
pieces for measuring the myeloperoxidase (MPO) enzyme activity
were frozen in liquid nitrogen and kept at freezer (85 1C)
(Minaiyan et al., 2013).
Furthermore, ulcer area was measured by Fiji-win 32 software,
an image processing and analysis software inspired by NIH Image
for the Macintosh (Ghosh et al., 2004). For each specimen ulcer
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index was calculated using the following equation as described by
Varshosaz et al. (2010).
Ulcer index¼Ulcer area cm2 þMacroscopic score
2.8. Assay for myeloperoxidase (MPO) activity
Tissue MPO activity was carried out to measure neutrophil
accumulation. According to the technique described by Bradley
et al. (1982) with some modiﬁcation, segments of the colon (0.1 g)
were chopped to small pieces and homogenized in 1 ml of 50 mM
potassium phosphate (pH¼6) with 0.5% HTAB in an ice bath using
polytron homogenizer. More buffers were added to obtain a concen-
tration equivalent to 5 ml per 0.1 g of colon tissue. The resultant
homogenate was sonicated in an ice bath for 10 s, then subjected to a
sequence of freezing and thawing 3 times, and sonicated again for
10 s and centrifuged for 15 min at 15,000 rpm at 4 1C. A 0.1 ml of the
supernatant was mixed with 2.9 ml of 50 mM phosphate buffer
(pH¼6) containing 0.167 mg/ml O-dianisidine dihydrochloride and
0.0005% hydrogen peroxide. The change in absorbance at 460 nmwas
measured using a UV/VIS spectrophotometer (LSI Model Alfa-1502).
2.9. Histopathological evaluation of colon damage
Sections of colon specimens were ﬁxed in formalin solution
(10%), dehydrated, embedded in parafﬁn, sliced into 5 μm-thick
sections, deparafﬁnized with xylene, hydrated and stained with
hematoxylin and eosin (H&E) respectively and then scored accord-
ing to the criteria previously described by Dieleman et al. (1998)
(Table 1). Total colitis index was measured by summing the scores
of inﬂammation severity, inﬂammation extent and crypt damage
(Minaiyan et al., 2011).
2.10. Statistical analysis
Results are expressed as mean7S.E.M for parametric data and
median (range) for non-parametric data. The data was analyzed by
one-way ANOVA followed by TUKEY post hoc test for multiple
comparisons. For histopathological data, a non-parametric test
(Kruskal–Wallis test) with Mann–Whitney U test was employed. All
statistical analyses were assessed using Graph Pad Prism (ver. 5.04)
software. nPo0.05, nnPo0.01 and nnnPo0.001 (in the ﬁgures).
3. Results
3.1. Assessment of anti-depressant dose of ﬂuvoxamine using forced
swimming test
Induction of depression by single administration of reserpine
(6 mg/kg, i.p.) in Res group signiﬁcantly increased immobility time
compared to Sham group (Po0.01). As illustrated in Fig. 1, ﬂuvox-
amine at doses of 2.5, 5, and 10mg/kg reduced this immobility in
reserpinized rats (Po0.001). Having distinguished their anti-
depressant effects in FST following four days treatment, these three
doses of ﬂuvoxamine were selected for evaluating in the colitis part of
this study.
3.2. Change in animals' body weight
As shown in Fig. 2, induction of experimental colitis caused loss
of body weight during ﬁve days experiment in control group.
Administration of reserpine (6 mg/kg, i.p.) in Res group caused the
same body weight loss as in the control group (Fig. 1B). Rats
treated with dexamethasone (1 mg/kg, i.p.) as a reference drug
and ﬂuvoxamine (2.5, 5 mg/kg, i.p.) showed a signiﬁcant
improvement of the wasting disease in day 4 and/or day 5 com-
pared with control group. However following ﬁve days experi-
ment, rats in Sham group gained body weight.
3.3. Effect of ﬂuvoxamine on macroscopic features
Following induction of colitis, the colons of control group
showed severe inﬂammation, ulceration, wall thickening and
edema and also necrosis. These colonic damages were more
intense in reserpine treated group (Res, 6 mg/kg, i.p.); whereas
colons of Sham group showed intact epithelium with no damage.
As illustrated in Figs. 3 and 4, weight of distal colon and ulcer
index (summation of ulcer area and macroscopic score) was
signiﬁcantly increased in control and Res group ﬁve days after
colitis induction (Po0.001). Moreover, treatment with dexa-
methasone (1 mg/kg, i.p.) as a reference drug, reduced both weight
Fig. 1. Effect of ﬂuvoxamine (1.25, 2.5, 5, and 10 mg/kg, i.p.) on duration of
immobility (seconds) during forced swimming test in reserpinized (6 mg/kg, i.p.)
rats. Res¼reserpine (6 mg/kg), i.p.¼ intraperitoneally. Results are presented as
mean7S.E.M (n¼6). nnPo0.01 and nnnPo0.001 compared to Res; one-way
ANOVA followed by Tukey test.
Fig. 2. Effect of ﬂuvoxamine (2.5, 5, and 10mg/kg, i.p.) on body weight change (g) in
rats with acetic acid colitis. Treatments were administered 2 h after acetic acid
instillation and daily thereafter for 4 consecutive days. A: normal rats, B: reserpinized
(6 mg/kg, i.p.) depressed rats; i.p.¼ intraperitoneally, Dex. 1¼dexamethasone (1 mg/kg),
Res¼reserpine (6 mg/kg). Results are expressed as mean7S.E.M (n¼6). nPo0.05,
nnPo0.01 and nnnPo0.001 compared to control, one-way ANOVA followed by
Tukey test.
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of colon (Po0.01) and ulcer index (Po0.001) in Dex. 1 group
compared with the acetic acid-control group. Fluvoxamine pro-
duced a signiﬁcant reduction of weight of colon in both reserpi-
nized and non-reserpinized rats at doses of 2.5 and 5 mg/kg
(Po0.01, Po0.05, respectively) (Fig. 3). Compared with control
group, ﬂuvoxamine at dose of 2.5 mg/kg showed a signiﬁcant
reduction in ulcer index (Po0.01) in both reserpinized and non-
reserpinized animals whereas ﬂuvoxamine at dose of 5 mg/kg
just in non-reserpinized rats reduced ulcer index signiﬁcantly
(Po0.05) but not in reserpinized depressed rats Fig. 5.
3.4. Effect of ﬂuvoxamine on histopathological features
In Sham group, no histological damage was observed and colonic
mucosa has an intact epithelium. In contrast, control group included
transmural necrosis, edema and diffuse inﬂammatory cell inﬁltra-
tion in the mucosa, desquamated areas and loss of epithelium. An
inﬁltrate consisting of mixed inﬂammatory cells was observed
(Fig. 6). Administration of reserpine (6 mg/kg, i.p.) in Res group
exacerbated histopathological damages additionally (Fig. 6C). In rats
treated with dexamethasone (1 mg/kg, i.p.) histopathological scores
including inﬂammation severity, inﬂammation extent, crypt
damage and total colitis index were signiﬁcantly decreased
(Po0.01). In non-reserpinized groups, treatment of rats with
ﬂuvoxamine (2.5, 5 mg/kg, i.p.) reduced colonic damage as evalu-
ated in histopathological score reduction. Also, total colitis index
in comparison with control group, was signiﬁcantly decreased
(Po0.01) (Table 1).
In reserpinized depressed groups, ﬂuvoxamine at doses of 2.5,
5 mg/kg also attenuated the histological scores (Fig. 6G and H).
As compared to control, these treatments brought about a decline
in total colitis index in injurious colons. However ﬂuvoxamine at a
dose of 10 mg/kg could not reduce the colonic damage while
evaluating histopathological features.
3.5. Effect of ﬂuvoxamine on myeloperoxidase (MPO) activity
The results of MPO activity correlated closely with other
parameters studied including macroscopic and pathologic. This
result conﬁrmed the histological assessment indicating increased
leukocyte inﬁltration to the control and Res groups and MPO
activity in the intestinal tissue of the control and Res groups was
signiﬁcantly increased (Po0.01) as compared to Sham group. In
contrast, MPO activity in dexamethasone treated rats (Po0.01)
and ﬂuvoxamine (2.5, 5 mg/kg, i.p.) treated groups (Po0.05)
decreased in depressed and non-depressed rats as compared with
control group Fig. 7.
4. Discussion
At ﬁrst, in a pilot study we showed that single administration of
reserpine at the speciﬁed dose (6 mg/kg, i.p.) signiﬁcantly (Po0.01)
increased duration of immobility in the FST four days later, so it is
interpreted that reserpine can induce depression during the time we
need to evaluate anti-colitic effects of ﬂuvoxamine; although, it has
been demonstrated that this anti-depressant drug, at selected doses
(2.5, 5, and 10mg/kg, i.p) reduced the immobility time four days after
single administration of reserpine, and so has anti-depressive effect
(Fig. 1). This model of depression is a suitable and discriminative
model for evaluating depressive or anti-depressive effects of
Fig. 3. Effect of ﬂuvoxamine (2.5, 5, and 10 mg/kg, i.p.) on weight of distal colon. A:
normal rats, B: reserpinized (6 mg/kg, i.p.) depressed rats; i.p.¼ intraperitoneally,
Dex. 1¼dexamethasone (1 mg/kg), Res¼reserpine (6 mg/kg). Results are presented
as mean7S.E.M (n¼6). nPo0.05, nnPo0.01 and nnnPo0.001 compared to control,
one-way ANOVA followed by Tukey test.
Fig. 4. Effect of ﬂuvoxamine (2.5, 5, and 10 mg/kg, i.p.) on ulcer index. A: normal
rats, B: reserpinized (6 mg/kg, i.p.) depressed rats; i.p.¼ intraperitoneally, Dex.
1¼dexamethasone (1 mg/kg), Res¼reserpine (6 mg/kg). Results are presented as
mean7S.E.M (n¼6). nnPo0.01 and nnnPo0.001 compared to control, one-way
ANOVA followed by Tukey test.
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reserpineor ﬂuvoxamine respectively. In a recent study, depression
was induced by injection of reserpine (6 mg/kg, i.p.) and then the anti-
depressive effect was evaluated by FST (Bolandghamat et al., 2011).
Clinically effective SSRIs are active in the forced swimming test
(Kuśmider et al., 2007).
In colitic part of the experiment, acetic acid-induced colitis was
used. It is a well-characterized model, which resembles to human
colitis (MacPherson and Pfeiffer, 1978). It was shown that colonic
inﬂammation is characterized by increased neutrophils inﬁltration
into the intestinal tissue, edema, ulceration and necrosis. Our
Fig. 5. Photographs of colonic tissue ﬁve day after colitis induction in rats. (a) Normal colon; (b) acetic acid-control rat; (c) reserpinized (6 mg/kg, i.p.) colitic rat;
(d) treatment with dexamethasone(1 mg/kg, i.p.) in colitic rat; (e, f) treatment with ﬂuvoxamine (2.5, 5 mg/kg, i.p.) in colitic rats; (g,h) treatment with ﬂuvoxamine (2.5,
5 mg/kg, i.p.) in reserpinized (6 mg/kg, i.p.) colitic rats.
Fig. 6. Effect of ﬂuvoxamine treatment on experimental colitis in rat. (A) Appearance of a normal rat colon. (B) Appearance of a control colitic rat colon: associated with
mucosal layers destruction with inﬂammatory cell inﬁltration and crypt damage. (C) Appearance of an acetic acid-treated rat colon in reserpinized (6 mg/kg, i.p.) depressed
rat: associated with great mucosal layer destruction with more inﬂammatory cell inﬁltration and cryptic damage. (D–F) Appearance of an acetic acid rat colon treated with
dexamethasone (1 mg/kg, i.p.), ﬂuvoxamine (2.5 mg/kg, i.p.), ﬂuvoxamine (5 mg/kg, i.p.) in non-depressed rats. (G, H) Colitis tissue treated with ﬂuvoxamine (2.5 mg/kg, i.p.),
ﬂuvoxamine (5 mg/kg, i.p.) in reserpinized (6 mg/kg, i.p.) depressed rats: associated with attenuating the extent and severity of the histological cell damage; i.p.¼
intraperitoneally, H&E staining, Original magniﬁcation 10.
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ﬁndings showed that treatment with ﬂuvoxamine at lower doses
(2.5 or 5 mg/kg) markedly attenuated the colonic damage in acetic
acid-colitis in reserpinized depressed rats and non-resepinized
rats. Decreased body weight loss and colonic weight/length ratio,
reduced colonic macroscopic and microscopic damage scores and
inhibited MPO activity were the criteria for improvement. Further-
more, induction of depression by reserpine (6 mg/kg, i.p.) exacer-
bated the colitis damage in reserpine-treated group. The results of
this study are consistent with ﬁndings of recent studies indicating
that depressive-like behavior is associated with an exaggerated
response to inﬂammatory stimuli in the gut, using 2 models of
depression induction of maternally separated (MS) (Varghese
et al., 2006) and i.c.v. administration of reserpine (Ghia et al.,
2008, 2009). Both maternally separated and reserpine (1 μg/d, i.c.
v) induced depressed mice showed evidence of depressive like
behavior in tail suspension test and enhanced intestinal perme-
ability after colitis induction by DSS or DNBS (dinitrobenzene
sulfonic acid). Impaired parasympathetic function and reduction in
acetylcholine level was mentioned as a basis for the vulnerability
of reserpinized mice to colitis. Treatment with the anti-depressant
drug, desmethylimipramine reversed the behavioral change and
protected against this vulnerability to colitis in depressed mice. In
the current study ﬂuvoxamine at doses of 2.5 and 5 mg/kg
improved the colitic status in both depressed and non-depressed
animals; while in the mentioned experiment, the anti-depressant
did not inﬂuence inﬂammation in the absence of depression.
Combination of pharmacological models (reserpine-induced
depression, forced swimming test and acetic acid-induced colitis)
in our study, were used in order to show the depression impact on
clinical course of colitis and also to show the salutary effect of anti-
depressant therapy in IBD patients. In another study the anti-
inﬂammatory effect of ﬂuoxetine and desipramine at two doses
(10 and 20 mg/kg/day) were reported in acetic-acid induced colitis
in rats. Fluoxetine was shown to have anti-inﬂammatory effect at
lower dose (10 mg/kg) only in normal rats (Guemei et al., 2008)
while our study evaluated the effect of ﬂuvoxamine in both
normal and depressed animals to discriminate the effect of
depression on colitis additionally.
Rajesh et al. (2013) showed that following treatment with
Tribulus terrestriss extract at a dose of 160 mg/kg, body weight
loss showed signiﬁcant protection (57%) against DSS-induced
colitis. The results of the current study also showed that ﬂuvox-
amine at lower dose (2.5 mg /kg) reduced the body weight loss in
both normal and depressed animals (Fig. 2).
Psycho–neuro–endocrine–immune modulation through the
brain–gut axis likely has a key role in the pathogenesis of
inﬂammatory bowel disease (IBD) (Prins, 2011). Qiu et al. (1999)
demonstrated that colitis induction in mice by DNBS can subse-
quently be reactivated by environmental stresses which are due to
reduction of colonic mucin and increased colon permeability. This
vulnerability to environmental stress is perceived initially by the
CNS, which responds to environmental stimuli by modulating
inﬂammatory or immune response through a complex network
of signals that communicate with the intestine (Hollander, 2003).
This theory conﬁrmed why depression induction following reser-
pine injection exacerbates colitis and why treatment with ﬂuvox-
amine improved intestinal inﬂammation.
Selective serotonin reuptake inhibitors (SSRIs), which are pre-
scribed for anxiety, have also been used for treating inﬂammatory,
chronic and neuropathic pain. Acute SSRI administration increases
brain extracellular serotonin and the anti-nociceptive effect of SSRI
was considered to be induced via serotonin (5-HT) receptor
activities (Hayashi et al., 2009). We conclude that increasing brain
serotonin level following ﬂuvoxamine treatment may have direct
anti-inﬂammatory effects to reduce inﬂammatory conditions in
the gut.
It has been reported that numbers and content of mast cells
and other immune cells increase in the inﬂamed colonic tissue
(He, 2004). Anti-depressants following increasing monoamine
levels and activating monoamine receptors inhibit LPS or
Fig. 7. Effect of ﬂuvoxamine (2.5, 5, and 10 mg/kg, i.p.) on myeloperoxidase (MPO)
enzyme activity in the colonic tissue. A: normal rats, B: reserpinized (6 mg/kg, i.p.)
depressed rats; i.p.¼ intraperitoneally, Dex. 1¼dexamethasone (1 mg/kg), Res¼reser-
pine (6 mg/kg). Results are presented as mean7S.E.M (n¼6). nPo0.05 and nnPo0.01
compared to control, one-way ANOVA followed by Tukey test.
Table 1
Effect of ﬂuvoxamine (Flu, 2.5, 5, and 10 mg/kg, i.p.) on pathologic parameters of
colitis induced by acetic acid in normal and reserpinized (6 mg/kg, i.p.) depressed
(RFlu, 2.5, 5, and 10) rats.
Groups Inﬂammation
severity (0–3)
Inﬂammation
extent (0–3)
Crypt damage
(0–4)
Total colitis
index (0–10)
Sham 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0)
Control 3 (2–3)a 3 (2–3)a 4 (1–4)a 9.5 (6–10)a
Dex. 1 0.5 (0–1)c 0 (0–2)c 0 (0–2)c 1 (0–5)c
Flu. 2.5 1 (0–2)c 1 (0–2)c 1 (0–2)b 3 (1–6)c
Flu. 5 0.5 (0–3)b 0.5 (0–2)c 1 (0–2)b 2.5 (1–6)c
Flu. 10 2 (1–3) 2 (1–3) 2.5 (1–4) 5.5 (5–10)
Res 3 (1–3) 3 (1–3) 4 (1–4) 10 (4–10)
RFlu.
2.5
1 (0–2)c 1 (0–2)c 0.5 (0–3)b 2.5 (1–4)c
RFlu. 5 1.5 (1–2)b 1.5 (1–3)b 2 (0–2)b 4.5 (2–7)b
RFlu.
10
2.5 (1–3) 2 (1–3) 2 (0–4) 5.5 (5–10)
Dex. 1¼dexamethasone (1 mg/kg), Res¼reserpine (6 mg/kg), Flu¼Fluvoxmine,
RFlu¼reserpinized (6 mg/kg, i.p.) colitic rats treated with ﬂuvoxamine, i.p.¼
intraperitoneally. Values are presented as median (range) (n¼6).
a Po0.01 compared to Sham.
b Po0.05.
c Po0.01 compared to control, Mann–Whitney U test.
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IFN-gamma evoked inﬂammatory transactivations through the up-
regulation of cAMP/PKA pathway in intestinal immune cells
(Hashioka et al., 2009). Inhibition of NF-κB signaling causes to
inhibit activation of gene expression of iNOS (inducible nitric oxide
synthase) and various pro-inﬂammatory cytokine. It is one of the
plausible mechanisms with which ﬂuvoxamine may decrease
inﬂammatory mediator from intestinal immune cells. Koh et al.
(2011) showed that preventive and therapeutic administration
of ﬂuoxetine, another SSRI anti-depressant can ameliorate DSS-
induced colitis in mice. The mentioned mechanism in the study
was that ﬂuoxetine directly inhibits NF-κB signaling in intestinal
epithelial cells (IEC) and ameliorates experimental colitis.
Although ﬂuvoxamine is a SSRI drug with similar properties as
ﬂuoxetine, it is conferred from the study that beneﬁcial effect of
ﬂuvoxamine in the acetic acid colitis in both normal and depressed
rats is to some extent mediated through inhibition of NF-kB
signaling in IEC. Modulation of 5-HT release from IEC is critical
to normal and perhaps abnormal gastrointestinal function
(Galligan, 2004). Recent studies declared that, inhibition of 5HT3
receptor by ondansetron (Motavallian et al., 2012), granisetron
(Fakhfouri et al., 2010) or tropisetron (Motavallian et al., 2013) has
salutary effect on experimental colitis in rat. It is justiﬁed that
serotoninergic receptors and in particular, 5HT3 receptor were
found in immune cells including macrophages and play an
important role in inﬁltration and activation of macrophages in
intestinal inﬂammation. However the results of our study have no
controversies to the result of the mentioned studies because of
diversity of serotonergic receptors and their roles in the gastro-
intestinal system. The reason for ineffectiveness of ﬂuvoxamine at
higher dose (10 mg/kg) may be due to overcoming of serotonergic
drive and then activating the mentioned receptor in macrophage.
Similar study with Guemei et al. (2008) also showed that ﬂuox-
etine only at lower dose (10 mg/kg) has beneﬁcial effect in acetic
acid colitis whereas a dose of 20 mg/kg had also been evaluated.
Administration of a SSRI drug in a short period of time
stimulates the hypothalamo–pituitary–adrenal (HPA) axis. The
increase in synaptic 5-HT concentration and activation of post-
synaptic 5-HT receptors is responsible for the immediate increase
in hormonal output via the HPA axis after SSRI treatment. This
action is mediated through postsynaptic 5-HT1A and 5-HT2 recep-
tors which lead to corticosterone release, a well-known endogen-
ous substance with strong anti-inﬂammatory property, from
the adrenal cortex (Mikkelsen et al., 2004). Anti-inﬂam-
matory effect of ﬂuvoxamine in this model of colitis may be
to some extent thorough this mechanism. In addition, anti-
inﬂammatory effect of ﬂuvoxamine in a rat model of inﬂammation
was demonstrated. Hajhashemi et al. (2010b) had shown that
following i.p. administration of ﬂuvoxamine before or after sub-
plantar injection of carrageenan considerably inhibited paw
edema response at 4 h post-carrageenan (Po0.001), and this
anti-inﬂammatory effect was mediated through HPA axis and
glucocorticoid receptor which mifepristone inhibited the effect.
In this regard, we have speculated that the beneﬁcial effects of
ﬂuvoxamine on ulcerative colitis are mainly mediated through
these mechanisms including stimulating the HPA axis and corti-
costerone release, inhibition of NF-κB signaling pathways in the
inﬂammatory cell and reducing pro-inﬂammatory cytokine and
NO levels and modulating brain–gut axis through increasing
neural serotonin level.
In conclusion, the results of this study have clinical importance.
Our ﬁndings support the need for identiﬁcation and management
of depressive mood in IBD patients instead of merely attributing
depressed mood to the severity of the disease. It is suggested that
routine screening of IBD patients for depressive disorders, espe-
cially at the time of ﬁrst diagnosis and during disease ﬂares is
helpful to add an anti-depressive drug to the patient drug
regimen. Also based on our ﬁndings ﬂuvoxamine can be a good
candidate to treat depression comorbidities in people with IBD.
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